Table 1. The clinical characteristics of patients with NK/T-cell lymphoma.
| Parameters a n (%) | Total | D-Dimer < 1.2 μg/mL | D-Dimer ≥ 1.2 μg/mL | P value |
|---|---|---|---|---|
| Overall | 84 (100) | 61 (100) | 23 (100) | |
| Male gender | 57 (67.9) | 40 (65.6) | 17 (73.9) | 0.466 |
| Age (years) | 43 (11–77) | 41 (16–77) | 49 (11–75) | 0.140 |
| Age ≥ 60 years | 15 (17.9) | 10 (16.3) | 5 (21.7) | 0.568 |
| ECOG score ≥ 2 | 20 (23.8) | 4 (6.6) | 16 (69.6) | < 0.001 |
| Ann Arbor stage | ||||
| I-II | 63 (75.0) | 54 (88.5) | 9 (39.1) | < 0.001 |
| III-IV | 21 (25.0) | 7 (11.5) | 14 (60.9) | |
| B symptoms | 55 (65.5) | 34 (55.7) | 21 (91.3) | 0.002 |
| Elevated LDH | 30 (35.7) | 13 (21.3) | 17 (73.9) | < 0.001 |
| Involvement of regional lymph nodes | 34 (40.5) | 19 (31.1) | 15 (65.2) | 0.005 |
| Extranodal sites ≥ 2 | 18 (21.4) | 7 (11.5) | 11 (47.8) | < 0.001 |
| IPI score | ||||
| Low risk (0–1) | 61 (72.6) | 53 (86.9) | 8 (34.8) | < 0.001 |
| Intermediate risk (2–3) | 9 (10.7) | 6 (9.8) | 3 (13.0) | |
| High risk (4–5) | 14 (16.7) | 2 (3.3) | 12 (52.2) | |
| NKPI score | ||||
| Low risk (0) | 19 (22.6) | 18 (29.5) | 1 (4.3) | < 0.001 |
| Intermediate risk (1–2) | 40 (47.6) | 34 (55.7) | 6 (26.1) | |
| High risk (3–4) | 25 (29.8) | 9 (14.8) | 16 (69.6) | |
| Treatment modalities | ||||
| Chemotherapy alone | 28 (33.3) | 15 (24.6) | 13 (56.5) | < 0.001 |
| RT ± chemotherapy | 51 (60.7) | 46 (75.4) | 5 (21.7) | |
| Best supportive care alone | 5 (6.0) | 0 (0.0) | 5 (21.7) | |
| Chemotherapeutic regimen | ||||
| Asparaginase-containing | 25 (33.3) | 18 (31.6) | 7 (38.9) | 0.566 |
| Asparaginase-absent | 50 (66.7) | 39 (68.4) | 11 (61.1) |
ECOG: Eastern Cooperative Oncology Group; IPI: International Prognostic Index; LDH: lactate dehydrogenase; NKPI: natural killer/T-cell lymphoma prognostic index; RT: radiotherapy.
a Continuous variables are presented as medians (range), and categorical variables are shown as frequencies and percentages.